Progress Noted In Psoriasis treatment

Pharmaceutical products developer York Pharma said it has progressed in the development of a new topical treatment for psoriasis. The group said it has selected Carbenoxolone as its lead compound for a new class of drugs termed Vitamin A Metabolic Pathway inhibitors. "To date, in vitro and in vivo study results supporting the use of carbenoxolone in psoriasis have all been positive," said the group. It added that Phase II results further supported carbenoxolone as a new treatment for psoriasis. "York is pleased that these preliminary Phase II data indicate the potential of carbenoxolone for the treatment of this condition, and that the company's dermatology pipeline is continuing to make significant progress," said chief executive Terry Sadler.